最新ニュース Latham Group (NASDAQ:SWIM) 株価情報

Latham Group

Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.

Latham Group Inc

Sun Communities shares are trading higher after the company announced the sale of Safe Harbor Marinas to Blackstone for $5.65 billion.

Stifel analyst J. Bruce Chan upgrades Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) from Hold to Buy and raises the price target from $193 to $200.

News

Upgrades

Price Target

Analyst Ratings

ODFL

Stifel Upgrades Old Dominion Freight Line to Buy, Raises Price Target to $200

Stifel analyst W. Andrew Carter upgrades Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) from Hold to Buy and raises the price target from $100 to $110.

Stifel Upgrades Floor & Decor Hldgs to Buy, Raises Price Target to $110

WIIM

RGA shares are trading higher after the company announced a reinsurance transaction with Equitable Holdings.

Guggenheim analyst Seamus Fernandez reiterates Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) from Buy to Buy.

Reiteration

ARQT

Guggenheim Reiterates Buy on Arcutis Biotherapeuticsto Buy

Financial giants have made a conspicuous bullish move on Oklo. Our analysis of options history for Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) revealed 24 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 29% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $1,070,992, and 10 were calls, valued at $505,658.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $70.0 for Oklo over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Oklo's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Oklo's whale activity within a strike price range from $5.0 to $70.0 in the last 30 days. 
<h3>Oklo Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740410152_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$37.6</td>
<td>$36.75</td>
<td>$37.02</td>
<td>$70.00</td>
<td>$222.2K</td>
<td align="right">26</td>
<td align="right">40</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$33.45</td>
<td>$32.8</td>
<td>$33.12</td>
<td>$65.00</td>
<td>$165.5K</td>
<td align="right">12</td>
<td align="right">0</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$24.5</td>
<td>$22.6</td>
<td>$22.6</td>
<td>$20.00</td>
<td>$131.3K</td>
<td align="right">733</td>
<td align="right">7</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$10.1</td>
<td>$9.25</td>
<td>$10.1</td>
<td>$47.00</td>
<td>$101.0K</td>
<td align="right">367</td>
<td align="right">100</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.5</td>
<td>$6.2</td>
<td>$6.49</td>
<td>$31.00</td>
<td>$77.7K</td>
<td align="right">178</td>
<td align="right">120</td>
</tr>
</tbody>
</table>

<h3>About Oklo</h3>
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
In light of the recent options history for Oklo, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Oklo Standing Right Now?</h3>
<ul>
<li>With a volume of 4,248,387, the price of OKLO is down -8.76% at $35.39. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<h3>What Analysts Are Saying About Oklo</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $51.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Oklo, maintaining a target price of $58. 
&#x2A; An analyst from Craig-Hallum has revised its rating downward to Buy, adjusting the price target to $44. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Oklo, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

OKLO

What the Options Market Tells Us About Oklo

Stifel analyst Mathew Blackman initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Buy rating and announces Price Target of $25.

Initiation

BBNX

Stifel Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $25

Whales with a lot of money to spend have taken a noticeably bullish stance on Nebius Group.
Looking at options history for Nebius Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>) we detected 43 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 32% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $770,918 and 33, calls, for a total amount of $2,195,284.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $75.0 for Nebius Group over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Nebius Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Nebius Group's significant trades, within a strike price range of $30.0 to $75.0, over the past month.
<h3>Nebius Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740410147_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NBIS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$7.7</td>
<td>$7.3</td>
<td>$7.51</td>
<td>$35.00</td>
<td>$375.5K</td>
<td>9.0K</td>
<td align="right">16</td>
</tr>
<tr>
<td>NBIS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.6</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$45.00</td>
<td>$180.4K</td>
<td>12.6K</td>
<td align="right">277</td>
</tr>
<tr>
<td>NBIS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$18.0</td>
<td>$17.5</td>
<td>$17.75</td>
<td>$50.00</td>
<td>$177.5K</td>
<td>281</td>
<td align="right">150</td>
</tr>
<tr>
<td>NBIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.6</td>
<td>$50.00</td>
<td>$156.6K</td>
<td>2.6K</td>
<td align="right">163</td>
</tr>
<tr>
<td>NBIS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$29.5</td>
<td>$29.0</td>
<td>$29.0</td>
<td>$60.00</td>
<td>$145.0K</td>
<td>104</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Nebius Group</h3>
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&amp;D hubs across Europe, North America and Israel.
Having examined the options trading patterns of Nebius Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Nebius Group</h3>
<ul>
<li>Trading volume stands at 7,548,375, with NBIS's price down by -10.96%, positioned at $35.47.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 155 days.</li>
</ul>
<h3>What Analysts Are Saying About Nebius Group</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $55.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from BWS Financial persists with their Buy rating on Nebius Group, maintaining a target price of $51. 
&#x2A; An analyst from BWS Financial has decided to maintain their Buy rating on Nebius Group, which currently sits at a price target of $60. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nebius Group with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

NBIS

Nebius Group's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bearish approach towards Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PLTR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 120 extraordinary options activities for Palantir Technologies. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 40% leaning bullish and 42% bearish. Among these notable options, 93 are puts, totaling $5,373,589, and 27 are calls, amounting to $1,602,925.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $140.0 for Palantir Technologies during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Palantir Technologies's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Palantir Technologies's substantial trades, within a strike price spectrum from $70.0 to $140.0 over the preceding 30 days.
<h3>Palantir Technologies Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740410142_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$1.34</td>
<td>$1.3</td>
<td>$1.34</td>
<td>$100.00</td>
<td>$123.1K</td>
<td>8.8K</td>
<td>12.3K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$6.0</td>
<td>$5.9</td>
<td>$6.0</td>
<td>$96.00</td>
<td>$84.6K</td>
<td>1.7K</td>
<td>5.6K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.65</td>
<td>$7.65</td>
<td>$7.65</td>
<td>$80.00</td>
<td>$82.6K</td>
<td>5.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$90.00</td>
<td>$80.0K</td>
<td>11.5K</td>
<td>36.5K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$8.4</td>
<td>$8.25</td>
<td>$8.32</td>
<td>$100.00</td>
<td>$74.0K</td>
<td>16.0K</td>
<td>8.9K</td>
</tr>
</tbody>
</table>

<h3>About Palantir Technologies</h3>
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
After a thorough review of the options trading surrounding Palantir Technologies, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Palantir Technologies's Current Market Status</h3>
<ul>
<li>Trading volume stands at 47,448,132, with PLTR's price down by -9.2%, positioned at $92.03.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 70 days.</li>
</ul>
<h3>Expert Opinions on Palantir Technologies</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $101.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Palantir Technologies with a target price of $105. 
&#x2A; An analyst from Loop Capital has revised its rating downward to Buy, adjusting the price target to $141. 
&#x2A; Showing optimism, an analyst from Morgan Stanley upgrades its rating to Equal-Weight with a revised price target of $95. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Palantir Technologies, maintaining a target price of $125. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Underperform rating for Palantir Technologies, targeting a price of $40. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Palantir Technologies with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

PLTR

Behind the Scenes of Palantir Technologies's Latest Options Trends

Guggenheim analyst Eddie Hickman reiterates Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) from Buy to Buy.

TARS

Guggenheim Reiterates Buy on Tarsus Pharmaceuticalsto Buy

Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) has outperformed the market over the past 20 years by 2.22% on an annualized basis producing an average annual return of 10.55%. Currently, Lockheed Martin has a market capitalization of $104.35 billion. 
Buying $1000 In LMT: If an investor had bought $1000 of LMT stock 20 years ago, it would be worth $7,422.07 today based on a price of $443.32 for LMT at the time of writing.
<h3>Lockheed Martin's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740410109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Guggenheim analyst Subbu Nambi reiterates Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Buy.

BRKR

Guggenheim Reiterates Buy on Brukerto Buy

Nike shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $75 to $115.

Guggenheim analyst Robert Drbul reiterates Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and maintains $100 price target.

Guggenheim Reiterates Buy on Walmart, Maintains $100 Price Target

Guggenheim analyst Seamus Fernandez reiterates Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) from Buy to Buy.

MLYS

Guggenheim Reiterates Buy on Mineralys Therapeuticsto Buy

Guggenheim analyst Michael Morris reiterates Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and maintains $675 price target.

SPOT

Guggenheim Reiterates Buy on Spotify Technology, Maintains $675 Price Target

Guggenheim analyst Subbu Nambi reiterates Guardant Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) with a Buy and maintains $56 price target.

Guggenheim Reiterates Buy on Guardant Health, Maintains $56 Price Target

Guggenheim analyst Shahriar Pourreza reiterates Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) with a Neutral and maintains $57 price target.

Guggenheim Reiterates Neutral on Alliant Energy, Maintains $57 Price Target

The U.S. Securities and Exchange Commission has officially ended <a href="https://www.benzinga.com/markets/equities/25/01/42971991/robinhood-agrees-to-45-million-sec-settlement-over-past-violations">its investigation into</a> Robinhood's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) cryptocurrency operations without imposing any enforcement action, the company announced on Monday.
This development signals a potential shift in regulatory oversight following a period of heightened scrutiny on digital asset firms.
What Happened: Robinhood stated that the SEC's Enforcement Division sent a letter on Friday, confirming the conclusion of its inquiry.
The investigation, which began in May 2024, focused on Robinhood's crypto services, including asset listings, custody practices, and trading operations. 
At the time, the SEC had warned that the company could face charges over potential securities law violations.
Despite regulatory pressure, Robinhood maintained that it consistently worked with authorities to ensure compliance. 
&#8220;Robinhood Crypto has always operated within federal securities laws and has never facilitated securities transactions,&#8221; said Dan Gallagher, the company's chief legal and compliance officer. &#8220;We welcome the SEC's decision and a return to regulatory fairness.&#8221;
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43911115/grok-3-predicts-bitcoin-dominance-in-2025-projects-180000-price-target">Grok 3 Predicts Bitcoin Dominance In 2025, Projects $180,000 Price Target</a>
Why It Matters: The SEC's decision to close its investigation into Robinhood follows a similar move last week when it dropped <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43883117/coinbase-ceo-brian-armstrong-says-sec-has-agreed-to-end-bogus-enforcement-case-without-pen#:~:text=The%20SEC%20sued%20Coinbase%20in,service%20program%20violated%20securities%20laws.">an enforcement case against</a> Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
These actions suggest a potential regulatory shift that aligns with President Donald Trump's previously stated plans to support the crypto sector.
Many in the industry had criticized the SEC's enforcement-first approach under <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40568347/after-binance-and-coinbase-gary-gensler-led-sec-set-to-lock-horns-with-crypto-exchange-kra">former chair</a> Gary Gensler, arguing that it created uncertainty rather than providing clear regulations.
With the recent dismissals, expectations are rising that crypto firms may now operate with greater legal clarity.
Robinhood's crypto division has played a significant role in its overall business growth. 
In the fourth quarter, nearly half of the company's $672 million transaction-based revenue came from cryptocurrency trading, which saw a 700% increase as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged toward $100,000.
Investor sentiment toward Robinhood remains positive, with the company's stock rising more than 1% in premarket trading. 
Year-to-date, Robinhood shares have climbed 38%, reflecting growing confidence in a regulatory environment that could be more favorable to digital assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43901027/bybit-offers-140m-bounty-in-wake-of-14b-eth-hack-investigation-focuses-on-safe">Bybit Offers $140M Bounty In Wake of $1.4B ETH Hack, Investigation Focuses On Safe</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

HOOD

SEC Drops Investigation Into Robinhood's Crypto Unit

On Monday, the U.S Food and Drug Administration (FDA) lifted the clinical hold on Entrada Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) ENTR-601-44. The agency issued the hold in <a href="https://www.benzinga.com/news/22/12/30136373/why-entrada-therapeutics-stock-is-diving-after-hours" target="_blank" rel="noreferrer noopener">December 2022</a>.
In November 2023, despite providing additional information to the FDA, the company was informed that the agency declined to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35921201/why-is-neuromuscular-disease-focused-entrada-therapeutics-shares-trading-lower-toda" rel="noreferrer noopener">lift the clinical hold</a>.
The agency authorized to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose (MAD) clinical study of ENTR-601-44 for Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable <a href="https://www.benzinga.com/pressreleases/25/02/g43908630/entrada-therapeutics-announces-fda-removal-of-clinical-hold-on-entr-601-44" target="_blank" rel="noreferrer noopener">to exon 44 skipping</a>.
The global ELEVATE-44 program, which includes the ELEVATE-44-102 study in the U.S. and ELEVATE-44-201 outside of the U.S., will cover a broad population of patients with DMD and support evaluation of ENTR-601-44 in patients with both early and advanced disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43910538/why-is-penny-stock-co-diagnostics-trading-lower-on-monday" rel="noreferrer noopener">Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version</a>
&#8220;Given the strength of our safety and target engagement data from our Phase 1 clinical study and the profound unmet need in adults living with Duchenne, we are pleased to have obtained FDA clearance for the ELEVATE-44-102 study,&#8221; said Dipal Doshi, CEO of Entrada Therapeutics. &#8220;The study will help assess the potential of ENTR-601-44 in both non-ambulatory and ambulatory adult patients who are unfortunately often left out of clinical studies due to the advanced stage of their disease.&#8221;
ELEVATE-44-102 is a randomized, double-blind placebo-controlled Phase 1b study evaluating the safety and tolerability of ENTR-601-44 in approximately 32 non-ambulatory and ambulatory adult patients with DMD who are exon 44 skipping amenable.
The MAD study is also designed to evaluate target engagement as measured by exon skipping and dystrophin production as well as pharmacokinetics.
Dosing will be administered every six weeks, with the planned doses across four cohorts anticipated to range from 0.16 mg/kg up to 1.28 mg/kg.
Study participants may be eligible to enroll in an open-label extension study (OLE) in which the safety, efficacy and tolerability of ENTR-601-44 will be evaluated over a longer period of time.
The company plans to initiate study enrollment in the first half of 2026.
Price Action: TRDA stock is up 5.44% at $13.75&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43908370/amd-reshapes-strategy-plans-4-billion-data-center-asset-sale-while-doubling-down-on-gpus" target="_blank" rel="noreferrer noopener">AMD Reshapes Strategy, Plans $4 Billion Data Center Asset Sale While Doubling Down on GPUs</a></li>
</ul>
Photo Shutterstock

Comments

Latham Group

ニュース

最新ニュース Latham Group (NASDAQ:SWIM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル